Faster stroke treatment in specialized ambulances reduces patients' disability

Faster stroke treatment in specialized ambulances reduces patients' disability

Immune system may target other remote areas of the brain to improve stroke recovery Mobile stroke units are ambulances staffed with emergency medicine neurologists and equipped with a CT scanner and a lab designed to enable specific stroke treatment at the scene. Prehospital treatment consisted of administering medications to dissolve the clot blocking blood flow in or to the brain (ischemic stroke). Timing is key because the clot-busting medication alteplase should be administered within 4.5 hours of stroke symptoms. Researchers found that: 60% of patients assigned to the mobile stroke unit received clot-busting treatment with alteplase if a mobile stroke unit was available, compared to 48% of patients who received conventional treatment in the hospital; the time to treatment was shortened by an average of 20 minutes when a mobile stroke unit was dispatched; and the use of a mobile stroke unit reduced the likelihood and severity of disability and death at three months by 26%. While we had anticipated better outcomes in the patients treated in the mobile stroke units, we are amazed by the magnitude of the effects. It is obvious that clot-busting treatment is most effective if it is applied in the ultra-early phase of stroke - ideally within the first or 'golden hour' of symptom onset." Heinrich Audebert, M.D., lead study author, professor in the department of neurology and Center for Stroke Research at Charité Universitätsmedizin in Berlin Since treatment within the first hour of symptom onset happens rarely in conventional care, Audebert said health care providers should consider ways to optimize treatment so it can begin while in route to the hospital. "Stroke treatment is more effective the earlier it starts," he said. "Just waiting until the patient arrives at the hospital is not enough anymore." Source:



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More